Literature DB >> 20669305

Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease.

Jan O Aasly1, Carles Vilariño-Güell, Justus C Dachsel, Philip J Webber, Andrew B West, Kristoffer Haugarvoll, Krisztina K Johansen, Mathias Toft, John G Nutt, Haydeh Payami, Jennifer M Kachergus, Sarah J Lincoln, Amela Felic, Christian Wider, Alexandra I Soto-Ortolaza, Stephanie A Cobb, Linda R White, Owen A Ross, Matthew J Farrer.   

Abstract

Genealogical investigation of a large Norwegian family (F04) with autosomal dominant parkinsonism has identified 18 affected family members over four generations. Genetic studies have revealed a novel pathogenic LRRK2 mutation c.4309 A>C (p.Asn1437His) that co-segregates with disease manifestation (LOD = 3.15, θ = 0). Affected carriers have an early age at onset (48 ± 7.7 SD years) and are clinically asymmetric and levodopa responsive. The variant was absent in 623 Norwegian control subjects. Further screening of patients from the same population identified one additional affected carrier (1 of 692) with familial parkinsonism who shares the same haplotype. The mutation is located within the Roc domain of the protein and enhances GTP-binding and kinase activity, further implicating these activities as the mechanisms that underlie LRRK2-linked parkinsonism.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20669305      PMCID: PMC2970614          DOI: 10.1002/mds.23265

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  18 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews.

Authors:  Laurie J Ozelius; Geetha Senthil; Rachel Saunders-Pullman; Erin Ohmann; Amanda Deligtisch; Michele Tagliati; Ann L Hunt; Christine Klein; Brian Henick; Susan M Hailpern; Richard B Lipton; Jeannie Soto-Valencia; Neil Risch; Susan B Bressman
Journal:  N Engl J Med       Date:  2006-01-26       Impact factor: 91.245

3.  Lrrk2 and Lewy body disease.

Authors:  Owen A Ross; Mathias Toft; Andrew J Whittle; Joseph L Johnson; Spiridon Papapetropoulos; Deborah C Mash; Irene Litvan; Mark F Gordon; Zbigniew K Wszolek; Matthew J Farrer; Dennis W Dickson
Journal:  Ann Neurol       Date:  2006-02       Impact factor: 10.422

Review 4.  Genetics of Parkinson disease: paradigm shifts and future prospects.

Authors:  Matthew James Farrer
Journal:  Nat Rev Genet       Date:  2006-04       Impact factor: 53.242

5.  Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations.

Authors:  Jennifer Kachergus; Ignacio F Mata; Mary Hulihan; Julie P Taylor; Sarah Lincoln; Jan Aasly; J Mark Gibson; Owen A Ross; Timothy Lynch; Joseph Wiley; Haydeh Payami; John Nutt; Demetrius M Maraganore; Krzysztof Czyzewski; Maria Styczynska; Zbigniew K Wszolek; Matthew J Farrer; Mathias Toft
Journal:  Am J Hum Genet       Date:  2005-02-22       Impact factor: 11.025

6.  Lrrk2 pathogenic substitutions in Parkinson's disease.

Authors:  Ignacio F Mata; Jennifer M Kachergus; Julie P Taylor; Sarah Lincoln; Jan Aasly; Timothy Lynch; Mary M Hulihan; Stephanie A Cobb; Ruey-Meei Wu; Chin-Song Lu; Carlos Lahoz; Zbigniew K Wszolek; Matthew J Farrer
Journal:  Neurogenetics       Date:  2005-09-17       Impact factor: 2.660

Review 7.  Epidemiology of Parkinson's disease.

Authors:  Lonneke M L de Lau; Monique M B Breteler
Journal:  Lancet Neurol       Date:  2006-06       Impact factor: 44.182

8.  Clinical features of LRRK2-associated Parkinson's disease in central Norway.

Authors:  Jan O Aasly; Mathias Toft; Ignacio Fernandez-Mata; Jennifer Kachergus; Mary Hulihan; Linda R White; Matthew Farrer
Journal:  Ann Neurol       Date:  2005-05       Impact factor: 10.422

Review 9.  LRRK2 in Parkinson's disease: protein domains and functional insights.

Authors:  Ignacio F Mata; William J Wedemeyer; Matthew J Farrer; Julie P Taylor; Kathleen A Gallo
Journal:  Trends Neurosci       Date:  2006-04-17       Impact factor: 13.837

Review 10.  Diagnostic criteria for Parkinson disease.

Authors:  D J Gelb; E Oliver; S Gilman
Journal:  Arch Neurol       Date:  1999-01
View more
  41 in total

1.  CSF Nrf2 and HSPA8 in Parkinson's disease patients with and without LRRK2 gene mutations.

Authors:  David A Loeffler; Lynnae M Smith; Mary P Coffey; Jan O Aasly; Peter A LeWitt
Journal:  J Neural Transm (Vienna)       Date:  2015-11-03       Impact factor: 3.575

Review 2.  In Vitro Modeling of Leucine-Rich Repeat Kinase 2 G2019S-Mediated Parkinson's Disease Pathology.

Authors:  Scott C Vermilyea; Marina E Emborg
Journal:  Stem Cells Dev       Date:  2018-03-29       Impact factor: 3.272

3.  Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study.

Authors:  Owen A Ross; Alexandra I Soto-Ortolaza; Michael G Heckman; Jan O Aasly; Nadine Abahuni; Grazia Annesi; Justin A Bacon; Soraya Bardien; Maria Bozi; Alexis Brice; Laura Brighina; Christine Van Broeckhoven; Jonathan Carr; Marie-Christine Chartier-Harlin; Efthimios Dardiotis; Dennis W Dickson; Nancy N Diehl; Alexis Elbaz; Carlo Ferrarese; Alessandro Ferraris; Brian Fiske; J Mark Gibson; Rachel Gibson; Georgios M Hadjigeorgiou; Nobutaka Hattori; John P A Ioannidis; Barbara Jasinska-Myga; Beom S Jeon; Yun Joong Kim; Christine Klein; Rejko Kruger; Elli Kyratzi; Suzanne Lesage; Chin-Hsien Lin; Timothy Lynch; Demetrius M Maraganore; George D Mellick; Eugénie Mutez; Christer Nilsson; Grzegorz Opala; Sung Sup Park; Andreas Puschmann; Aldo Quattrone; Manu Sharma; Peter A Silburn; Young Ho Sohn; Leonidas Stefanis; Vera Tadic; Jessie Theuns; Hiroyuki Tomiyama; Ryan J Uitti; Enza Maria Valente; Simone van de Loo; Demetrios K Vassilatis; Carles Vilariño-Güell; Linda R White; Karin Wirdefeldt; Zbigniew K Wszolek; Ruey-Meei Wu; Matthew J Farrer
Journal:  Lancet Neurol       Date:  2011-08-30       Impact factor: 44.182

Review 4.  Tied up: Does altering phosphoinositide-mediated membrane trafficking influence neurodegenerative disease phenotypes?

Authors:  Sravanthi S P Nadiminti; Madhushree Kamak; Sandhya P Koushika
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

Review 5.  Genetics of Parkinson disease and essential tremor.

Authors:  Christian Wider; Owen A Ross; Zbigniew K Wszolek
Journal:  Curr Opin Neurol       Date:  2010-08       Impact factor: 5.710

Review 6.  Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications.

Authors:  Iakov N Rudenko; Mark R Cookson
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

Review 7.  The genetics of Parkinson's disease: progress and therapeutic implications.

Authors:  Andrew B Singleton; Matthew J Farrer; Vincenzo Bonifati
Journal:  Mov Disord       Date:  2013-01       Impact factor: 10.338

8.  ARHGEF7 (Beta-PIX) acts as guanine nucleotide exchange factor for leucine-rich repeat kinase 2.

Authors:  Karina Haebig; Christian Johannes Gloeckner; Marta Garcia Miralles; Frank Gillardon; Claudia Schulte; Olaf Riess; Marius Ueffing; Saskia Biskup; Michael Bonin
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

Review 9.  Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance.

Authors:  Dena G Hernandez; Xylena Reed; Andrew B Singleton
Journal:  J Neurochem       Date:  2016-04-18       Impact factor: 5.372

Review 10.  LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.

Authors:  Yulan Xiong; Valina L Dawson; Ted M Dawson
Journal:  Biochem Soc Trans       Date:  2012-10       Impact factor: 5.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.